<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315614</url>
  </required_header>
  <id_info>
    <org_study_id>2000/0024</org_study_id>
    <secondary_id>R01DK056953</secondary_id>
    <nct_id>NCT00315614</nct_id>
  </id_info>
  <brief_title>Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus</brief_title>
  <official_title>Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients With Type 1 Diabetes Mellitus; Steroid Free Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECIFIC AIMS:

        -  To reverse hyperglycemia and insulin dependency in patients with Type 1 diabetes
           mellitus by islet cell transplantation.

        -  To induce a state of donor specific tolerance and eliminate the need for continuous
           immunosuppressive therapy by simultaneous transplantation of donor bone marrow cells
           with islets and utilization of the monoclonal antibody Campath-1H for induction of
           Immunosuppression.

        -  To assess long-term function of successful islet cell transplants in patients with Type
           1 diabetes mellitus.

        -  To determine whether the natural history of the microvascular, macrovascular and
           neuropathic complications are altered following successful transplantation of islet
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our current protocol (IRB #2000/0024) the immunosuppressive regimen, comprised of
      induction with daclizumab and maintenance therapy with sirolimus and tacrolimus, has been
      combined with the infusion of CD34+ enriched donor bone marrow stem cells in an attempt to
      create a chimeric state and hence induce donor tolerance. This strategy was tested by
      evaluating graft survival following the removal of all immunosuppressive medication after
      one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>A Reduction or Absence of Rejection Episodes</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The Induction of Multilineage Chimerism</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Independence or Reduction in Exogenous Insulin Requirements (Partial Graft Function), as Evidenced by Basal C-peptide Greater Than 0.5 ng/ml Prior to Weaning of Immunosuppression;</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Metabolic Control as Evidenced by Improvement in:</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C (Should be &lt; 6.5%),</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Amplitude of Glycemic Excursions (MAGE),</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose Meter Readings,</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGMS (Continuous Glucose Monitoring System)</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination or Reduction in the Incidence of Hypoglycemic Coma or Unawareness;</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in or Decreased Progression of Microvascular, Macrovascular and Neuropathic Complications of Diabetes.</measure>
    <time_frame>for the duration of islet graft function</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>islet transplant and CD34 Bone Marrow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>islet transplantation and infusion of CD34 enriched Bone Marrow cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islet Transplantation</intervention_name>
    <description>Islet transplantation</description>
    <arm_group_label>islet transplant and CD34 Bone Marrow</arm_group_label>
    <other_name>Islet</other_name>
    <other_name>type 1 DM</other_name>
    <other_name>Bone marrow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients between 18 and 65 years of age

          2. Patients with type 1 diabetes mellitus for more than 5 years duration

          3. One or more of the following:

               -  Hypoglycemia unawareness - judged by history of blood sugars &lt;54 on glucometer
                  without symptoms and/or hypoglycemic episodes requiring assistance from either
                  family, glucagon administration or emergency services

               -  Poor diabetes control (HbA1c&gt;8% or &gt;2 visits/yr to hospital for treatment of
                  ketoacidosis) despite intensive insulin therapy

               -  Progressive complications of type 1 diabetes mellitus

          4. Body Mass Index (BMI) â‰¤26

        Exclusion Criteria:

          1. Untreated proliferative diabetic retinopathy;

          2. HbA1C &gt; 12%;

          3. Insulin requirement &gt; 1.0u/kg/d

          4. Stimulated or basal C-peptide &gt; 0.3 ng/ml

          5. Creatinine clearance &lt; 60 and/or serum creatinine consistently &gt; 1.5mg/dl;

          6. Macroalbuminuria &gt; 300mg albumin in 24 hours

          7. Presence of panel reactive antibodies &gt; 20%;

          8. Previous/concurrent organ transplantation (except failed islet cell transplantation);

          9. Any medical condition requiring chronic use of steroids;

         10. Malignancy or previous malignancy (except non-melanomatous skin cancer);

         11. X-ray evidence of pulmonary infection;

         12. Active infections;

         13. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis
             can be provided)

         14. Active peptic ulcer disease,

         15. Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound;

         16. Serological evidence of HIV, HBV (HBsAg+ and/or HBcAb+ and/or HBsAb+ without evidence
             of vaccination), HTLV-1 or HCV;

         17. Negative serology for Epstein Barr virus (EBV) or evidence of acute infection
             (IgM&gt;IgG);

         18. Abnormal liver function test;

         19. Anemia (hemoglobin &lt;12.0 g/dl);

         20. Hyperlipidemia (fasting total cholesterol &gt;240mg/dl and/or fasting triglycerides
             &gt;200mg/dl and/or fasting LDL cholesterol&gt;140mg/dl);

         21. Body Mass Index above 26 and/or weight &gt;80kg;

         22. Prostate specific antigen (PSA) &gt; 4 ng/ml;

         23. Unstable cardiovascular status (including positive stress echocardiography if &gt;age
             35);

         24. Active alcohol or substance abuse;

         25. Sexually active females who are not: a) post-menopausal, b) surgically sterile, or c)
             not using an acceptable method of contraception (oral contraceptives, Norplant,
             Depo-Provera, and barrier devices are acceptable; condoms used alone are not
             acceptable);

         26. Positive pregnancy test or intent for future pregnancy, or male subject's intent to
             procreate.

         27. Any condition or any circumstances that makes it unsafe to undergo an islet cell
             transplant.

         28. History of previous transplant or previous bone marrow infusion.

         29. Persistent leucopenia (white blood cell count &lt;3,000/mm3
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetesresearch.org</url>
    <description>Diabetes Research Institute web site</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2006</firstreceived_date>
  <firstreceived_results_date>December 20, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Islet Transplantation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplantation and CD34 Bone Marrow</title>
          <description>Islet Transplantation: Islet transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplantation and CD34 Bone Marrow</title>
          <description>Islet Transplantation: Islet transplantation</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation and CD34 Bone Marrow</title>
            <description>Islet Transplantation: Islet transplantation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Achievement of Persistent Islet Function Following Cessation of Immunosuppression.</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>A Reduction or Absence of Rejection Episodes</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Induction of Multilineage Chimerism</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independence or Reduction in Exogenous Insulin Requirements (Partial Graft Function), as Evidenced by Basal C-peptide Greater Than 0.5 ng/ml Prior to Weaning of Immunosuppression;</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Metabolic Control as Evidenced by Improvement in:</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1C (Should be &lt; 6.5%),</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Amplitude of Glycemic Excursions (MAGE),</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose Meter Readings,</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGMS (Continuous Glucose Monitoring System)</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination or Reduction in the Incidence of Hypoglycemic Coma or Unawareness;</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in or Decreased Progression of Microvascular, Macrovascular and Neuropathic Complications of Diabetes.</title>
        <time_frame>for the duration of islet graft function</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplantation and CD34 Bone Marrow</title>
          <description>Islet Transplantation: Islet transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rodolfo Alejandro</name_or_title>
      <organization>University of Miami</organization>
      <phone>3052435324</phone>
      <email>ralejand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
